[go: up one dir, main page]

Agrati et al., 2022 - Google Patents

The immune response as a double‐edged sword: The lesson learnt during the COVID‐19 pandemic

Agrati et al., 2022

View PDF
Document ID
4847548493569561451
Author
Agrati C
Carsetti R
Bordoni V
Sacchi A
Quintarelli C
Locatelli F
Ippolito G
Capobianchi M
Publication year
Publication venue
Immunology

External Links

Snippet

The COVID‐19 pandemic has represented an unprecedented challenge for the humanity, and scientists around the world provided a huge effort to elucidate critical aspects in the fight against the pathogen, useful in designing public health strategies, vaccines and therapeutic …
Continue reading at onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Similar Documents

Publication Publication Date Title
Agrati et al. The immune response as a double‐edged sword: The lesson learnt during the COVID‐19 pandemic
Fodor et al. Endothelial Dysfunction, Inflammation, and Oxidative Stress in COVID‐19—Mechanisms and Therapeutic Targets
Pietrobon et al. I mmunosenescence and inflammaging: risk factors of severe COVID-19 in older people
Mueller et al. Why does COVID-19 disproportionately affect older people?
Triggle et al. A comprehensive review of viral characteristics, transmission, pathophysiology, immune response, and management of SARS-CoV-2 and COVID-19 as a basis for controlling the pandemic
Karki et al. Innate immunity, cytokine storm, and inflammatory cell death in COVID-19
Cicco et al. Neutrophil extracellular traps (NETs) and damage‐associated molecular patterns (DAMPs): two potential targets for COVID‐19 treatment
Aboudounya et al. COVID‐19 and toll‐like receptor 4 (TLR4): SARS‐CoV‐2 may bind and activate TLR4 to increase ACE2 expression, facilitating entry and causing hyperinflammation
Perico et al. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19
Soumya et al. Impact of COVID-19 on the cardiovascular system: a review of available reports
Dhochak et al. Pathophysiology of COVID-19: why children fare better than adults?
Melenotte et al. Immune responses during COVID-19 infection
Guihot et al. Cell-mediated immune responses to COVID-19 infection
Cardone et al. Lessons learned to date on COVID-19 hyperinflammatory syndrome: considerations for interventions to mitigate SARS-CoV-2 viral infection and detrimental hyperinflammation
Jodele et al. Tackling COVID‐19 infection through complement‐targeted immunotherapy
Aleksova et al. COVID‐19 and renin‐angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2)‐Is there any scientific evidence for controversy?
Kaushik et al. TLR4 as a therapeutic target for respiratory and neurological complications of SARS-CoV-2
Arish et al. COVID‐19 immunopathology: from acute diseases to chronic sequelae
Ellison-Hughes et al. The role of MSC therapy in attenuating the damaging effects of the cytokine storm induced by COVID-19 on the heart and cardiovascular system
Rotulo et al. Understanding COVID-19 in children: immune determinants and post-infection conditions
Ojha et al. Platelet factor 4 promotes rapid replication and propagation of Dengue and Japanese encephalitis viruses
Darwish et al. Mesenchymal stromal (stem) cell therapy fails to improve outcomes in experimental severe influenza
Jiang et al. CXCR5+ CD8+ T cells indirectly offer B cell help and are inversely correlated with viral load in chronic hepatitis B infection
Yan et al. Obesity and severe coronavirus disease 2019: molecular mechanisms, paths forward, and therapeutic opportunities
Rovito et al. Hallmarks of severe COVID-19 pathogenesis: a pas de deux between viral and host factors